Fruzaqla™ (fruquintinib) – New drug approval
November 8, 2023 - Takeda announced the FDA approval of Fruzaqla (fruquintinib), for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti- vascular endothelial growth factor (VEGF) therapy, and, if RAS wild-type and medically appropriate, an anti-epidermal growth factor receptor (EGFR) therapy.
Top